📊 CLCS Key Takeaways
Is Cell Source, Inc. (CLCS) a Good Investment?
Cell Source is in severe financial distress with negative stockholders' equity of -$18.9M, indicating liabilities exceed assets by nearly $19M. The company is cash-flow negative with operating losses of $3.2M against minimal revenue of -$124.8K, suggesting either business model failure or accounting issues. With only $23K in cash against $19.2M in total liabilities and a current ratio of 0.03x, the company faces imminent solvency risk.
Cell Source, Inc. shows extremely weak fundamentals, with minimal asset base, negligible cash, persistent operating and free cash flow losses, and deeply negative stockholders' equity. The reported improvement in net loss appears low quality because the business still lacks sustainable revenue generation and remains under severe liquidity and solvency pressure.
Why Buy Cell Source, Inc. Stock? CLCS Key Strengths
- No recent insider selling (0 Form 4 filings in last 90 days suggests limited insider confidence)
- Net loss and diluted EPS improved year over year from a very weak base
- Capital expenditure requirements appear minimal
- Long-term debt is limited relative to total liabilities, which suggests some liabilities may be non-debt in nature
CLCS Stock Risks: Cell Source, Inc. Investment Risks
- Negative stockholders' equity of -$18.9M indicates technical insolvency
- Negative revenue of -$124.8K suggests business failure or significant accounting adjustments
- Severe liquidity crisis with current ratio of 0.03x and only $23K cash against $19.2M liabilities
- Operating losses of $3.2M with no meaningful revenue generation
- High leverage with $3.5M long-term debt and -28.3x interest coverage ratio
- Negative operating cash flow of -$1.9M demonstrates inability to fund operations
- Severe liquidity distress, with only $22.99K cash and a 0.03x current ratio
- Negative equity of $18.94M indicates balance sheet insolvency and makes financial flexibility extremely limited
- Ongoing operating and free cash flow burn without evidence of durable revenue or profitable commercialization
Key Metrics to Watch
- Stockholders' equity trend and path to solvency
- Operating cash flow and runway to cash depletion
- Revenue stabilization and return to positive sales
- Quarterly operating cash burn relative to cash on hand
- Progress toward sustainable positive revenue and reduction in total liabilities
Cell Source, Inc. (CLCS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 1,553.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
CLCS Profit Margin, ROE & Profitability Analysis
CLCS vs Healthcare Sector: How Cell Source, Inc. Compares
How Cell Source, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cell Source, Inc. Stock Overvalued? CLCS Valuation Analysis 2026
Based on fundamental analysis, Cell Source, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cell Source, Inc. Balance Sheet: CLCS Debt, Cash & Liquidity
CLCS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cell Source, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.17 indicates the company is currently unprofitable.
CLCS Revenue Growth, EPS Growth & YoY Performance
CLCS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2015 | N/A | -$556.6K | N/A |
| Q3 2014 | N/A | -$323.6K | N/A |
| Q2 2014 | N/A | -$496.3K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cell Source, Inc. Dividends, Buybacks & Capital Allocation
CLCS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cell Source, Inc. (CIK: 0001569340)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLCS
What is the AI rating for CLCS?
Cell Source, Inc. (CLCS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLCS's key strengths?
Claude: No recent insider selling (0 Form 4 filings in last 90 days suggests limited insider confidence). ChatGPT: Net loss and diluted EPS improved year over year from a very weak base. Capital expenditure requirements appear minimal.
What are the risks of investing in CLCS?
Claude: Negative stockholders' equity of -$18.9M indicates technical insolvency. Negative revenue of -$124.8K suggests business failure or significant accounting adjustments. ChatGPT: Severe liquidity distress, with only $22.99K cash and a 0.03x current ratio. Negative equity of $18.94M indicates balance sheet insolvency and makes financial flexibility extremely limited.
What is CLCS's revenue and growth?
Cell Source, Inc. reported revenue of $-124.8K.
Does CLCS pay dividends?
Cell Source, Inc. does not currently pay dividends.
Where can I find CLCS SEC filings?
Official SEC filings for Cell Source, Inc. (CIK: 0001569340) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLCS's EPS?
Cell Source, Inc. has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CLCS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cell Source, Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CLCS stock overvalued or undervalued?
Valuation metrics for CLCS: ROE of N/A (sector avg: 15%), net margin of 3,351.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CLCS stock in 2026?
Our dual AI analysis gives Cell Source, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CLCS's free cash flow?
Cell Source, Inc.'s operating cash flow is $-1.9M, with capital expenditures of $2.6K. FCF margin is 1,553.5%.
How does CLCS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 3,351.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).